P2.14-016 Pulmonary Resection After Curative Intent Chemoradiation for NSCLC

Abstract

adenocarcinomas (15.5 months vs 12.5 months). 35.7% of adenocarcinomas progressed either within the thorax or at distant sites compared to only 12.5% of SCC. However, in 93% of adenocarcinomas and 100% of SCC the original treated lesion did not progress. Those with no histology had LCR of 95% with a median OS of 12 months respectively. Conclusion: Our data suggests a trend towards slightly better OS and LCR with SCC over adenocarcinomas. More adenocarcinomas progressed both locally and at distant sites than SCC did. This information may be useful prognostically and it suggests adenocarcinomas may need closer follow-up post-SABR. Overall, our LCR is in line with published data.